Business
Exercise of Options, Equity Issue, Director/PDMR
Exercise of Options, Equity Issue, Director/PDMR.
About this update from Litigation Capital Management Ltd
[{"type":"text","content":"\n \n \n \n RNS Number : 7683Q\n Litigation Capital Management Ltd\n 29 October 2021\n \n \n \n \n 29 October 2021\n \n \n Litigation Capital Management Limited\n \n \n (\"LCM\" or the \"Company\")\n \n \n Exercise\n of Options, Issue of Equity, Director / PDMR Shareholding\n \n \n Litigation Capital Management Limited (AIM:LIT), a leading international alternate asset manager of disputes financing solutions, announces:\n \n \n Executive CEO\n \n \n On 27 October 2021 Patrick Moloney, Chief Executive Officer of the Company exercised 900,000 options (the \"Executive Options\") at an exercise price of A$1.00. The Company has agreed to issue and allot in total 900,000 new Ordinary Shares (\"Ordinary Shares\") in the capital of the Company to Patrick Moloney. \n Following Admission, Patrick Moloney will hold 10,153,258 shares and 8.55% of the issued share capital.\n \n \n The LCM Loan Share Plan (\"LSP\") will be utilised to pay the strike price.\n \n \n Non-Executive Directors\n \n \n On 27 October 2021 Seistend Pty Ltd, an entity associated with Dr David King, a non-executive director of the Company, exercised 600,000 options (the \"Non-Executive Options\") at an exercise price of A$1.00. The Company has agreed to issue and allot in total 600,000 new Ordinary Shares in the capital of the Company. \n \n \n The Executive Options and the Non-Executive Options were granted on 21 September 2016.\n \n \n The Company has made an application for the 1,500,000 Ordinary Shares to be admitted to trading on AIM (\"Admission\"). Admission is expected to become effective on 5 November 2021. \n \n \n Concurrently with the exercise, Seistend Pty Ltd, an entity associated with Dr David King sold 250,000 Ordinary Shares to Jonathan Moulds, Chairman of the Company, at a price of GBP £1.00.\n \n \n Following Admission, \n Seistend Pty Ltd, an entity associated with Dr David King,\n and Jonathan Moulds will hold 1,951,484 and 250,000 Ordinary Shares respectively, and 1.64% and 0.21% of the Company's 118,699,145 Ordinary Shares in issue, each with voting rights. \n \n \n This figure of 118,699,145 Ordinary Shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Comp...